418
Participants
Start Date
February 19, 2014
Primary Completion Date
April 2, 2018
Study Completion Date
April 2, 2018
albuvirtide
albuvirtide 320mg administered intravenously once a week
lopinavir-ritonavir
lopinavir-ritonavir 400/100mg administered orally twice daily
tenofovir
tenofovir 300mg administered orally once daily
lamivudine
lamivudine 300mg administered orally once daily
302 Hospital People's Liberation Army Of China, Beijing
Beijing Ditan Hospital, Capital Medical University, Beijing
Beijing Youan Hospital, Capital medical university, Beijing
Guangzhou Eighth People's Hospital, Guangzhou
The Third People'S Hospital Of Shenzhen, Shenzhen
Henan Infectious Disease Hospital, Zhengzhou
The First Hospital of Changsha, Changsha
The Second Xiangya Hospital of Central South University, Changsha
Shanghai Public Health Clinical Center, Shanghai
Tangdu Hospital, Fourth Military Medical University, Xi’an
Affiliated Hangzhou Xixi Hospital,Zhejiang University School Of Medicine, Hangzhou
The First Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou
Lead Sponsor
Frontier Biotechnologies Inc.
INDUSTRY